Development of attenuated bovine herpesvirus-4 as a safe, inexpensive, single dose vaccine to control Streptococcus suis infection in domestic pigs

疫苗是医学界最大的胜利之一，它几乎根除了几种致命的细菌性疾病。然而，今天使用的大多数疫苗都是由100多年前开创的技术开发的，并不能代表该领域的全部潜力。牛疱疹病毒疫苗(BoHV-4)是最有前景的新型疫苗之一，它结合了免疫持久性和低生产成本。在本项目中，我们将开发一种新型的BoHV-4疫苗来对抗猪链球菌。猪链球菌是一种影响世界各地猪农的主要疾病，也是一种危险的人畜共患病病原体。申请者将开发使用免疫原性猪链球菌蛋白的新型疫苗，然后在猪身上进行测试，以令人信服地证明有效性和抗生素使用量的可量化减少。我们的目标是首先在3年内将疫苗商业化-成本项目，然后在我们强大的BoHV-4平台内将其确立为旗舰产品，该平台可以治疗许多其他严重影响动物和人类健康的细菌感染。该项目具有创新性，因为目前还没有有效的疫苗来治疗和预防猪的猪链球菌病。

Vaccines are one of medicine's greatest triumphs, having led to the virtual eradication of several deadlybacterial diseases. However, most vaccines in use today were developed by techniques pioneered over 100years ago and do not represent the full potential of the field. Bovine herpes virus vaccines (BoHV-4) are one ofthe most promising classes of new vaccines, combining durability of immunity with low costs of manufacture.In this project, we will develop a novel BoHV-4 vaccine against S. suis - a major disease affecting pig farmersworldwide and a dangerous zoonotic pathogen in humans. The applicants will develop the novel vaccine usingimmunogenic S. suis proteins and then test it in pigs to convincingly demonstrate both efficacy and aquantifiable reduction in antibiotic usage. Our objectives are firstly to commercialize the vaccine within 3 yearspost-project and secondly establish it as a flagship product within our powerful BoHV-4 platform which can betargeted at many other serious bacterial infections affecting both animal and human health. The project isinnovative in that there are currently no effective vaccines for the treatment and prevention of S. suis in pigs